ALAMEDA, Calif., May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.
Event: | William Blair 45th Annual Growth Stock Conference |
Date: | Tuesday, June 3, 2025 |
Time: | 3:00pm ET/12:00pm PT |
Event: | Jefferies Global Healthcare Conference |
Date: | Wednesday, June 4, 2025 |
Time: | 9:55am ET/6:55am PT |
Event: | Truist Securities MedTech Conference |
Date: | Tuesday, June 17, 2025 |
Time: | 10:00am ET/7:00am PT |
Webcasts of the presentations can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following each event.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Investor Relations
Penumbra, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$314.27 |
| Daily Change: | -0.62 -0.20 |
| Daily Volume: | 234,263 |
| Market Cap: | US$12.310B |
December 29, 2025 November 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
